

REMARKS

The specification has been amended to provide a cross-reference to the previously filed International Application.

Claim 11 has been amended to remove the improper multi-dependency.

Entry of the Preliminary Amendment and favorable action on the merits are respectfully requested.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By *my/Well #36,623*  
Andrew D. Meikle, #32,868

ADM/ja:cqc

P.O. Box 747  
Falls Church, VA 22040-0747  
(703) 205-8000

Attachment: Version With Markings Showing Changes Made

**VERSION WITH MARKINGS SHOWING CHANGES MADE**

The claims have been amended as follows:

11. (Amended) An antigen comprising the recombinant protein from merozoite of *Babesia caballi* as set forth in [any of claims 4 to 6] claim 4.

## DESCRIPTION

GENE ENCODING PROTEIN FROM MEROZOITE OF *BABESIA CABALLI*,  
RECOMBINANT PROTEIN OBTAINED WITH SAID GENE AND USE THEREOF  
TECHNICAL FIELD

5           The present invention relates to a protein  
derived from a merozoite of *Babesia caballi* (hereinafter  
also referred to as "BC"), a kind of equine Protozoa  
*Babesia*, a gene encoding said protein, an antibody specific  
to said protein, and a method for diagnosing equine  
10 babesiasis using the same.

## BACKGROUND ART

Equine babesiasis is protozoiiasis carried by the  
mites. The pathogen of this disease is equine Protozoa  
*Babesia*, among which two species of *Babesia caballi* and  
15 *Babesia equi* (hereinafter also referred to as "BE") are  
known.

Equine babesiasis is widely spread all over the  
world including South Europe, Asia, Russia, the Middle and  
Near East, Africa, and Central and South America.  
20 Clinically, this disease has main symptoms of anemia and  
jaundice with high fever and progresses either acutely or  
chronically. In acute cases, its lethality reaches about  
10% or even as high as 50% in rare cases although it may  
somewhat vary with either of the two pathogens. On the  
25 other hand, the conditions after prognosis vary with either